Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Neoplasms 4Venous Thrombosis 2Venous Thromboembolism 2Pulmonary Embolism 2Thrombosis 1Prostatic Neoplasms 1Myeloproliferative Disorders 1Multiple Endocrine Neoplasia Type 1 1Hot Flashes 1Cushing Syndrome 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Advanced Non-small Cell Lung Cancer 1

Interventions

Gabapentin 6Acupuncture Therapy 4Venlafaxine Hydrochloride 3liposomal amphotericin B 2Tamoxifen 2Magnesium Oxide 2Isoflavones 2Citalopram 2Caspofungin 2zopiclone 1oxybutynin 1black cohosh root extract 1Zolpidem 1Vitamin B 6 1Vancomycin 1Testosterone 1Tazobactam 1Soybean Proteins 1Sodium Chloride 1Sertraline 1Pregabalin 1Piperacillin, Tazobactam Drug Combination 1Piperacillin 1N,N'-(1,4-phenylenebis(methylene))dipyrimidin-2-amine 1Moxifloxacin 1Mindfulness-Based Stress Reduction 1Mindfulness 1Mind-Body Therapies 1Megestrol Acetate 1Medroxyprogesterone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Hot Flashes × Dabigatran × Clear all
NCT05471817 2022-11-22

A Study to Learn How the Study Drug Elinzanetant (BAY 3427080) Affects the Way the Drug Dabigatran Moves Into, Through and Out of the Body in Healthy Male and Female Participants

Bayer

Phase 1 Completed
20 enrolled
Endocrine

Multiple Endocrine Neoplasia Type 1, Hot Flashes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡